CoChat

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease

Open access
LonDownS Consortium, Startin, Carla M., Ashton, Nicholas J., Hamburg, Sarah, Hithersay, Rosalyn, Wiseman, Frances K., Mok, Kin Y., Hardy, John, Lleó, Alberto, Lovestone, Simon, Parnetti, Lucilla, Zetterberg, Henrik, Hye, Abdul, Strydom, André · 2019 · Alzheimer's Research & Therapy
Cited by 85

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer’s disease (AD), driven by amyloid precursor protein ( APP ) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and controls will aid in understanding AD development in DS. We explored group differences in plasma concentrations of amyloid-β peptides and tau (as their accumulation is a characteristic feature of AD) and cytokines (as the inflammatory response has been implicated in AD development, and immune dysfunction is common in DS). We used ultrasensitive assays to compare plasma concentrations of the amyloid-β peptides Aβ 40 and Aβ 42 , total tau (t-tau), and the cytokines IL1β, IL10, IL6, and TNFα between adults with DS ( n = 31), adults with sAD ( n = 27), and controls age-matched to the group with DS ( n = 27), and explored relationships between molecular concentrations and with age within each group. In the group with DS, we also explored relationships with neurofilament light (NfL) concentration, due to its potential use as a biomarker for AD in DS. Aβ 40 , Aβ 42 , and IL1β concentrations were higher in DS, with a higher Aβ 42 /Aβ 40 ratio in controls. The group with DS showed moderate positive associations between concentrations of t-tau and both Aβ 42 and IL1β. Only NfL concentration in the group with DS showed a significant positive association with age. Concentrations of Aβ 40 and Aβ 42 were much higher in adults with DS than in other groups, reflecting APP gene triplication, while no difference in the Aβ 42 /Aβ 40 ratio between those with DS and sAD may indicate similar processing and deposition of Aβ 40 and Aβ 42 in these groups. Higher concentrations of IL1β in DS may reflect an increased vulnerability to infections and/or an increased prevalence of autoimmune disorders, while the positive association between IL1β and t-tau in DS may indicate IL1β is associated with neurodegeneration. Finally, NfL concentration may be the most suitable biomarker for dementia progression in DS. The identification of such a biomarker is important to improve the detection of dementia and monitor its progression, and for designing clinical intervention studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-019-0477-0

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 85

Metadata

Authors
LonDownS Consortium, Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok, K. Y., Hardy, J., Lleó, A., Lovestone, S., Parnetti, L., Zetterberg, H., Hye, A., & Strydom, A.
Venue
Alzheimer's Research & Therapy
Published
2019-03-21
Volume
11
Issue
1
Pages
26-26
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2917093389
Cited by
85
References
26
FWCI
7.86
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-019-0477-0
The paper
LonDownS Consortium, Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok, K. Y., Hardy, J., Lleó, A., Lovestone, S., Parnetti, L., Zetterberg, H., Hye, A., & Strydom, A. (2019). Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-019-0477-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.